Sanofi/Regeneron's Libtayo Pivotal Data Shines In Fourth Cancer Type
Phase III Trial In Cervical Cancer Stopped Early Due To Good OS Results
Executive Summary
The Sanofi/Regeneron PD-1 inhibitor Libtayo has become the first immunotherapy to demonstrate an improved overall survival in patients with cervical cancer in a Phase III trial.
You may also be interested in...
Regeneron Lifts Stake In Biotech Partner ISA Pharma
Armed with €26m in fresh funds from investors that include partner Regeneron, ISA Pharma can now advance promising preclinical assets generated from its proprietary platform, containing a mix of synthetic antigenic peptides, its CEO tells Scrip.
PD-1 Inhibitor Market Poised For A New Round Of Expansion: After GSK’s Jemperli Approval, US FDA Still Has Three Novel Candidates Under Review
Agenus’ recent submission of balstilimab joins novel checkpoint inhibitors from Incyte expecting FDA action this year; Junshi and Coherus’ ongoing rolling BLA for toripalimab is the first from the multiple PD-1/L1 inhibitor candidates developed in China that are vying to enter the US market.
Sanofi Q1 Preview: Building The Pipeline, Improving Business Efficiencies
Strong sales of Dupixent and its range of vaccines are expected to drive Sanofi’s financial results for the first quarter of 2021, although these are likely to have been adversely affected by currency exchange rate movements. Numerous data readouts are expected in the coming months from pipeline products.